secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2022-02-03T23:59:59+00:00
Accession:  0001104659-22-011130
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q4 2021 revenue $13.5B (+24%), Non-GAAP EPS $1.80; FY2022 guidance issued
-------------------------------------------------------------------------------

- Q4 2021 sales $13.5B (+24% YoY); GAAP EPS $1.51, Non-GAAP EPS $1.80 (vs $0.98).
- Full-year 2021 sales $48.7B (+17%); GAAP EPS $4.86, Non-GAAP EPS $6.02.
- KEYTRUDA FY sales $17.2B (+20%); GARDASIL/GARDASIL 9 sales $5.7B (+44%).
- Molnupiravir contributed $952M in Q4; Animal Health sales $5.6B (+18%).
- FY2022 guidance: sales $56.1-$57.6B, GAAP EPS $5.76-$5.91, Non-GAAP EPS $7.12-$7.27.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465922011130/0001104659-22-011130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465922011130/tm222755d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-011130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer